Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DTRA Awards $3.3 M Contract to Psioxus Therapeutics

Published: Friday, January 18, 2013
Last Updated: Friday, January 18, 2013
Bookmark and Share
PsiOxus Therapeutics, Ltd. has been awarded a $3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants.

PsiOxus will use the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates: the recombinant Protective Antigen (rPA) for Anthrax and the Venezuelan Equine Encephalopathy Virus (VEEV). PolyMAP is an immunotherapeutic platform that combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines.

“We are honoured to have received this contract from the DTRA and excited at the prospect of helping to improve the safety and efficacy of these two very important vaccine candidates using the PolyMAP technology,” said Dr. John Beadle, CEO of PsiOxus Therapeutics. “Adjuvant platforms are key to innovating and growing the global vaccine market, and we are confident that our immunotherapeutic platform PolyMAP, along with our oncolytic vaccines expertise and team of renowned scientists, will play a significant and long-term role in the future of the industry.”

The contract will support work over a three-year period in the US, as well as in the company’s new state-of-the-art laboratory in Oxford, which has been designed and equipped as a category two laboratory for the handling of live viruses. 

The global market for Human Vaccines is forecast to reach US$32.21 billion by the year 2017 1, with key factors such as the growing pediatric population, world travel, and addiction driving market growth. The potential for significant growth and uptake of therapeutic vaccines is expected to further add to this significant growth potential in the longer term.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PsiOxus to Release Study Results of Oncolytic Vaccine Enadenotucirev
Phase I studies to be presented at 2014 ASCO annual meeting.
Saturday, May 17, 2014
Myotec Merges with Hybrid Biosystems to Form PsiOxus Therapeutics
Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces the merger of its portfolio company Myotec Therapeutics Ltd. (Myotec) with Hybrid Biosystems Ltd. (Hybrid) to form PsiOxus Therapeutics.
Wednesday, December 15, 2010
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!